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Up until recently, attempts at immune modulation in lung cancer have failed to demonstrate a consistent impact 
on survival. Several promising novel strategies are currently 
being evaluated in clinical trials, with early evidence of activ-
ity. Two approaches of particular interest have been vac-
cines and immune checkpoint inhibition.The former enables 
enhanced exposure to tumor antigen whereas the latter aims to 
counteract physiologic mechanisms of immune tolerance co-
opted by some tumors. Below is a summary of specific immu-
notherapies presented during the 12th Targeted Therapies for 
Lung Cancer Meeting.
SUMMARY OF PRESENTATIONS
Introduction
Dr. Garilovich initiated the session on immunotherapy 
by discussing the role of combination treatment with che-
motherapy and immunotherapy. Despite initial concerns 
that chemotherapy would primarily interfere with immuno-
therapy because of immunosuppressive effects, observations 
from clinical trials combining vaccines and chemotherapy 
suggest that this may not be the case. Rather, chemotherapy 
may potentiate effects of immunotherapy, possibly by disrup-
tion of tumor stoma allowing more cytotoxic T lymphocytes 
(CTLs) to penetrate into tumors, reduction of immunosup-
pressive cells such as T regulatory cells within the tumor, and 
interference with production of tumor suppressive cytokines. 
According to Dr. Gabrilovich, an additional key mechanism 
of synergy seems to be chemotherapy induced up-regulation 
of the mannose-6-phosphate receptor on tumor cells. By 
mediating uptake of granzyme B into tumor cells, mannose-
6-phosphate receptors render  tumor cells more susceptible to 
lysis by CTLs, which release granzyme B on recognition of 
tumor-associated antigen. This effect is particularly important 
to neighboring tumor cells that do not express tumor antigen 
recognized by the CTLs.
Vaccines
Melanoma Antigen A3 Vaccine
The MAGE (melanoma antigen) genes constitute a fam-
ily of cancer-germline or cancer testis genes, whose expres-
sion is limited to the testes, placenta, and some cancers. 
Approximately 30% to 50% of non-small-cell lung cancers 
(NSCLCs) express MAGE-A3 on their surface, with higher 
expression in squamous cell carcinoma. The MAGE-A3 vac-
cine is a recombinant protein vaccine combined with the 
immunological adjuvant ASO2B. On the basis of encouraging 
phase II data,1 the ongoing phase III MAGE-A2 as Adjuvant 
Non-Small Cell LunG CanceR ImuunoTherapy (MAGRIT) 
trial is evaluating the MAGE-A3 vaccine as adjuvant therapy 
in patients with completely resected MAGE-A3 positive (by 
reverse transcription (RT)-polymerase chain reaction) stage 
IB, II, and IIIA NSCLC (NCT00480025). Patients are strati-
fied by receipt of adjuvant chemotherapy and then randomized 
in a 2:1 ratio to additional treatment with the MAGE-A3 vac-
cine or placebo (administered over 27 months). The primary 
endpoint of the trial is disease-free survival. On the basis of 
promising results from a 49 gene signature predicting benefit 
from the MAGE-A3 vaccine,2 the MAGRIT trial was recently 
amended to include disease-free survival in the gene signa-
ture positive patients as a coprimary objective. As of January 
2012, 14,000 patients had been screened and 2243 patients 
randomized to the MAGRIT study.
L-BLP-25 (Stimuvax)
Mucin-1 (MUC-1) is a cell surface mucinous glyco-
protein overexpressed or aberrantly glycosylated in a number 
of epithelial malignancies. Aberrant glycosylation seems to 
expose the core peptide of MUC-1 to immune effector cells. 
L-BLP-25 is a MUC-1 vaccine consisting of the BLP-25 
peptide, monophosphoryl lipid A adjuvant, and liposomal 
components, including cholesterol, dimyristoyl phosphati-
dylglycerol, as well as dipalmitoyl phosphatidylcholine to 
facilitate immune recognition. On the basis of an impressive 
subset analysis of stage IIIB patients in a randomized phase 
II trial evaluating maintenance BLP-25 in 1476 patients 
with advanced NSCLC,3 the ongoing phase III Stimulating 
Targeted Antigenic Responses To NSCLC (START) trial 
is evaluating BLP-25 as consolidation therapy after defini-
tive chemoradiation for unresectable stage III NSCLC 
(NCT00409188). The primary endpoint of the trial is overall 
survival (OS).
Belagenpumatucel (Lucanix)
One mechanism used by tumors to escape immune 
surveillance is secretion of transforming growth factor beta 
(TGF-β), which inhibits T and B cell activation, natural killer 
and lymphokine-activated killer cells, dendritic cell matura-
tion, and antigen presentation. TGF-β also induces immuno-
suppressive FoxP3 T regulatory cells. Belagenpumatucel is an 
allogenic whole tumor vaccine consisting of four irradiated 
NSCLC tumor cell lines modified to block TGF-β2 secretion. 
Injection of belagenpumatucel creates a microenvironment 
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devoid of TGF-β, leading to activated T cells refractory to 
inhibition by TGF-β. On the basis of encouraging survival 
data from a phase II clinical trial, a phase III study known as 
the STOP trial is currently underway randomizing patients 
with advanced NSCLC, who have no progression of disease 
after first-line chemotherapy to belagenpumatucel or pla-
cebo (NCT00676507). The primary endpoint of the trial is 
OS, with power to detect a 3.5 month difference in survival 
among 506 patients. As of February 9, 2012, 420 patients 
were enrolled.
Immune Checkpoint Inhibitors
Ipilimumab
Ipilimumab is a fully human monoclonal IgG1 antibody 
to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a 
coinhibitory transmembrane protein found on activated T cells 
and monocytes. CTLA-4 acts to dampen immune responses by 
competing with the stimulatory receptor, CD28 for B7.1 ligand 
expressed on antigen presenting cells. CTLA-4 is unregulated 
by T cell activation in attempts to limit T cell overactivity and 
has a higher affinity for B7.1 than CD28. By blocking CTLA-
4, ipilimumab restores T cell activation initiated by antigen 
presentation to the T cell receptor and subsequent CD28/ B7.1 
interaction. Ipilimumab is currently approved for use in meta-
static melanoma by the Food and Drug Administration. On the 
basis of activity seen in squamous cell NSCLC from a small, 
randomized, phase II trial of chemotherapy plus or minus 
ipilimumab,4 a phase III trial has been launched comparing 
carboplatin/paclitaxel with carboplatin/paclitaxel and iplili-
mumab in patients with chemo-naive advanced squamous 
cell carcinoma of the lung (NCT01285609). A phase III trial 
evaluating chemotherapy (cisplatin/etoposide) with or without 
ipilimumab for chemo-naive extensive stage small-cell lung 
cancer (SCLC) is also underway (NCT01450761).
Bristol-Myers Squibb-936558/Bristol-Myers 
Squibb-935559
The programmed death receptor 1 (PD1)/B7-H1 path-
way has emerged as an important regulator of immune acti-
vation in multiple tumor types, including NSCLC. PD1 can 
be found on CTLs, as well as other cells of the immune sys-
tem, and on interacting with its primary ligand, programmed 
death ligand 1 (PDL1 or B7-H1), which is expressed on some 
tumors, an inhibitory message is sent into the T cell leading 
to an inactivated or exhausted T cell phenotype. By blocking 
this interaction with Bristol-Myers Squibb (BMS)-936558, an 
IgG4 antibody to PD1, or BMS-936559, an IgG4 antibody to 
PDL1, T cell activation is restored, leading to immune attack 
on the tumor.
Dr. Brahmer presented data from two phase I trials eval-
uating each agent, respectively, which were later updated in 
the New England Journal of Medicine.5,6 Both trials consisted 
of a dose-escalation phase followed by a dose-expansion 
cohort in select malignancies. Patients were heavily pretreated 
for advanced disease (55% of NSCLC patients treated with 
BMS-936558 having received at least 3 prior treatments). 
In neither study was a maximum tolerated dose reached. 
Seventy-three of 122 NSCLC patients receiving BMS-936558 
were evaluable for response, with an 18% overall response 
rate and a progression-free survival (PFS) rate at 24 weeks 
of 26%.5 Forty-nine of 75 NSCLC patients receiving BMS-
936559 were evaluable for response, with a 10% response rate 
and a PFS rate at 24 weeks of 31%.6 Therapy was tolerated 
well, with grade 3/4 toxicity of 14% and 9%, respectively, in 
those receiving BMS-936558 or BMS-936559.
A phase I study of BMS-936558 combined with stan-
dard first-line chemotherapy for advanced NSCLC is currently 
underway, with expansion cohorts recently added, evaluating 
BMS-936558 in combination with erlotinib in patients with 
advanced EGFR mutant NSCLC, as maintenance therapy 
with bevacizumab, and alone as first-line therapy in advanced 
NSCLC (NCT01454102). A registration phase III trial is also 
close to opening comparing BMS-936558 with standard sec-
ond-line chemotherapy in advanced NSCLC.
AMP-224
B7-DC (or PD-L2), another ligand for PD1, is expressed 
on dendritic cells (DC) and macrophages. AMP-224 is a 
B7-DC Ig fusion protein that blocks the interaction between 
PD1 and B7-H1 on tumor infiltrating lymphocytes (TILs). In 
preclinical models, combination of AMP-224 with cyclophos-
phamide, used to deplete T regulatory cells in tumor-draining 
lymph nodes and tumor, leads to effective CTL response by 
reducing induction of PD1 and proliferation of PD1 positive 
TILs. These observations led to an ongoing phase 1 dose-
escalation trial of AMP-224 preceded by low-dose cyclophos-
phamide (NCT01352884).
Others
Talactoferrin
Talactoferrin is a recombinant human lactoferrin with 
immunomodulatory properties. After ingestion, talacto-
ferrin is believed to act on the gastrointestinal epithelium 
to release cytokines, which assist in recruiting dendritic 
cells to the gut-associated lymphoid tissue. Activated den-
dritic cells then initiate both innate immunity, via natural 
killer cells, and adaptive immunity by presenting antigens 
to CD8+ lymphocytes that seek out tumor. On the basis of 
encouraging phase II data,7,8 two phase III trials evaluating 
talactoferrin are underway. FORTIS- M is a randomized, 
double-blind, placebo-controlled study of oral talactoferrin 
versus best supportive care in patients with stage IIIB or IV 
NSCLC and Eastern Cooperative Oncology Group perfor-
mance status of 0 to 2, who have failed two or more prior 
regimens (NCT00707304). Patients are randomized in a 2:1 
ratio to talactoferrin or placebo, with primary endpoint of OS 
(planned n = 742). FORTIS-C is a randomized, double-blind, 
placebo-controlled study of oral talactoferrin in combination 
with carboplatin and paclitaxel in patients with untreated 
stage IIIB/IV NSCLC and Eastern Cooperative Oncology 
Group performance status of 0 to 1 (NCT00706862). In 
patients without progression of disease after six cycles, talac-
toferrin or placebo is continued up to 18 months if tolerable 
and disease progression is not appreciated. One thousand one 
hundred patients will be enrolled, with coprimary endpoints 
of PFS and OS.
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IMGN901
IMGN901 is an antibody drug conjugate consist-
ing of a humanized IgG1 antibody to CD56 linked to the 
microtubule inhibitor, mertansine (also known as DM-1). 
After binding to CD56, which is expressed extensively on 
neuroendocrine tumor cells including SCLC, IMGN901 is 
internalized and DM-1 is released into the cell. Two clinical 
trials of IMGN-901 enrolling lung cancer patients are cur-
rently active; a phase I dose-escalation trial in patients with 
CD56+ solid tumors with an expansion cohort of 40 patients 
(NCT00346385; dosing daily for 3 days every 3 weeks), and 
a phase I/II trial of combination therapy with carboplatin and 
etoposide (NCT01237678; dosing day 1 and 8 every 3 weeks 
with standard 3-day regimen of carboplatin and etoposide 
every 3 weeks; in those without progression of disease after 
six cycles, IMGN901 is continued alone).
Anticancer Viruses: SVV-001 and Reolysin
Seneca Valley Virus (SVV)-001 is a replication competent 
picovirus with selective tropism for tumors with neuroendocrine 
features. On the basis of preclinical studies finding antitumor 
activity with SVV-001, a phase I dose-escalation study was 
completed.9 No maximum tolerated dose was identified, and a 
phase II study of SVV-001 monotherapy is currently underway 
in patients with SCLC who have no evidence of progressive dis-
ease after four cycles of standard platinum-based chemotherapy 
(NCT01017601).
Reolysin is a natural occurring unmodified oncolytic 
virus. It was hypothesized that tumors driven by epidermal 
growth factor receptor (EGFR) or KRAS  signaling might be 
particularly susceptible to this virus as such signaling leads to 
protein kinase R deactivation (via dephosphorylation), which 
enables viral replication and subsequent cell lysis as phos-
phorylated protein kinase R interferes with translation of viral 
genes. A phase I/II trial investigating concurrent therapy with 
carboplatin and paclitaxel in patients with advanced NSCLC 
enrolled 14 patients with KRAS mutant and 14 patients with 
KRAS wild-type tumors.10 One partial response was reported 
in the 12 evaluable patients with KRAS mutant NSCLC (with 
8 patients achieving stable disease), and six in the KRAS wild-
type group (with an additional 6 patients with stable disease). 
All the responders in the KRAS wild-type group had EGFR 
amplification detected in their pretrial tumor specimens. 
Another ongoing trial is evaluating concurrent carboplatin/
paclitaxel and resoslyin in patients with advanced squamous 
cell NSCLC (NCT00861627).
FUTURE DIRECTIONS
Recent clinical studies have reinvigorated inter-
est in immunotherapy for lung cancer. Prolonged dramatic 
responses have been observed in a handful of patients, with 
good tolerance. It is now imperative to understand mecha-
nisms of sensitivity and resistance to such therapies, with 
goals toward selection of patients most likely to respond to 
specific immunotherapies. Serial blood tests and tumor biop-
sies from patients receiving immunotherapy, paired with pre-
clinical models, will guide the way.
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